Therapy Optimization in Multiple Sclerosis (MS)

N/ACompletedNCT00819000

Teva Neuroscience, Inc.2,878 enrolled

Overview

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

Study Type

OBSERVATIONAL

Enrollment

2,878

Conditions

Multiple Sclerosis

Interventions

Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1bDRUG

MS therapies (listed above) used according to prescribers' instructions.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, 18 years of age or older, with a diagnosis of MS. * Being treated with Glatiramer Acetate (GA) or (IFN)-β * Receiving therapy from a participating Specialty Pharmacy Exclusion Criteria: * Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study * Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP) * Unlikely to be able to participate for the full two years of the study

Locations (3)

Teva Investigational Site

Swartz Creek, Michigan, United States

Teva Investigational Site

Columbus, Ohio, United States

Teva Investigational Site

Carnegie, Pennsylvania, United States

Outcomes

Primary Outcomes

Relationship of therapy Medication Possession Ratio (MPR), to patient outcomes

Time frame: 12 months and 24 months

Secondary Outcomes

Relationship of therapy adherence, defined as the accumulation of time from initiation to discontinuation of therapy and measured by time, to patient outcomes

Time frame: 12 months and 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.